Search
Close this search box.

Highlights

Frail older adults taking cardiometabolic medications: When less is more

Chaitoff A, Haff N, Lauffenburger JC, Choudhry NK. Medication de-escalation opportunities among frail older adults with strictly-controlled cardiometabolic disease [published online ahead of print, 2023 Apr 4]. J Am Geriatr Soc. 2023;10.1111/jgs.18368. doi:10.1111/jgs.18368 Many patients with hypertension, diabetes, and heart disease benefit from cardiometabolic disease medications. However, the number of medications available and potential downstream […]

Frail older adults taking cardiometabolic medications: When less is more Read More »

From the hospital to the postacute care facility: How well is Shed-MEDS working?

Vasilevskis EE, Shah AS, Hollingsworth EK, et al. Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial. JAMA Intern Med. 2023;183(3):223-231. doi:10.1001/jamainternmed.2022.6545 Despite the well-known risks of polypharmacy among hospitalized older adults, few deprescribing interventions target initiating deprescribing in the hospital, and to date no deprescribing trial

From the hospital to the postacute care facility: How well is Shed-MEDS working? Read More »

How should we better measure the cost-effectiveness of deprescribing interventions? Recommendations for improving value assessment

Hung A, Wang J, Moriarty F, et al. Value assessment of deprescribing interventions: Suggestions for improvement [published online ahead of print, 2023 Feb 21]. J Am Geriatr Soc. 2023;10.1111/jgs.18298. doi:10.1111/jgs.18298 Despite the well-established link between deprescribing interventions and reduced use of potentially inappropriate medications (PIMs), there is little evidence behind the cost-effectiveness of these interventions.

How should we better measure the cost-effectiveness of deprescribing interventions? Recommendations for improving value assessment Read More »

Key learnings from the OPTIMIZE deprescribing pragmatic trial

Sheehan OC, Gleason KS, Bayliss EA, et al. Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial [published online ahead of print, 2022 Dec 12]. J Am Geriatr Soc. 2022;10.1111/jgs.18148. doi:10.1111/jgs.18148 Polypharmacy is a growing concern among older adults, especially those with cognitive impairment and Multiple Chronic Conditions (MCC). Cognitively impaired

Key learnings from the OPTIMIZE deprescribing pragmatic trial Read More »

Multiple Comorbidities and Multiple Medications: The Challenges Facing Older Adults with Heart Failure

Kwak MJ, Cheng M, Goyal P, et al. Medication Complexity Among Older Adults with HF: How Can We Assess Better?. Drugs Aging. 2022;39(11):851-861. doi:10.1007/s40266-022-00979-2 Heart failure affects 6 million Americans today, over half of whom are 75 and older. Older adults with heart failure face complex medication regimens that are further complicated by the cognitive,

Multiple Comorbidities and Multiple Medications: The Challenges Facing Older Adults with Heart Failure Read More »

How “age-friendly” are deprescribing interventions?

Wang J, Shen JY, Conwell Y, et al. How “age-friendly” are deprescribing interventions? A scoping review of deprescribing trials [published online ahead of print, 2022 Oct 11]. Health Serv Res. 2022;10.1111/1475-6773.14083. doi:10.1111/1475-6773.14083 The 4Ms (“Medication,” “Mentation,” “Mobility,” and “What Matters Most”) are considered essential components of age-friendly health systems. Age-friendly health systems are better equipped

How “age-friendly” are deprescribing interventions? Read More »

Deintensifying diabetes medications: Beliefs and misconceptions among older adults

Pilla SJ, Meza KA, Schoenborn NL, Boyd CM, Maruthur NM, Chander G. A Qualitative Study of Perspectives of Older Adults on Deintensifying Diabetes Medications [published online ahead of print, 2022 Sep 29]. J Gen Intern Med. 2022;10.1007/s11606-022-07828-3. doi:10.1007/s11606-022-07828-3 While previous studies have examined the patient perspective on deprescribing, few have explored this topic in relation

Deintensifying diabetes medications: Beliefs and misconceptions among older adults Read More »

Gabapentin as a substitute for opioids: Is the solution creating new problems?

Bongiovanni T, Gan S, Finlayson E, et al. Prolonged use of newly prescribed gabapentin after surgery [published online ahead of print, 2022 Aug 24]. J Am Geriatr Soc. 2022;10.1111/jgs.18005. doi:10.1111/jgs.18005 Postoperative pain management has changed significantly in the last decade. Surgeons have attempted to decrease opioid prescribing by using non-opioid “multimodal” pain regimens, such as

Gabapentin as a substitute for opioids: Is the solution creating new problems? Read More »

The Tool to Reduce Inappropriate Medications (TRIM): Can a clinical decision support tool promote deprescribing among primary care clinicians?

Mecca MC, Zenoni M, Fried TR. Primary care clinicians’ use of deprescribing recommendations: A mixed-methods study. Patient Educ Couns. 2022;105(8):2715-2720. doi:10.1016/j.pec.2022.04.013 The Tool to Reduce Inappropriate Medications (TRIM) provides individualized reports on patient medications, including medication reconciliation errors and potentially inappropriate medications (PIMs). A recent study published in Patient Education and Counseling explored the impact

The Tool to Reduce Inappropriate Medications (TRIM): Can a clinical decision support tool promote deprescribing among primary care clinicians? Read More »

Can N-of-1 trials inform deprescribing practices? Dr. Parag Goyal weighs in

Goyal P, Safford M, Hilmer SN, et al. N-of-1 Trials to Facilitate Evidence-Based Deprescribing: Rationale and Case Study [published online ahead of print, 2022 Jun 15]. Br J Clin Pharmacol. 2022;10.1111/bcp.15442. doi:10.1111/bcp.15442 Junior Investigator Intensive scholar Parag Goyal and a team of researchers recently published a narrative review on deprescribing-N-of-1 trials. N-of-1 trials compare treatment

Can N-of-1 trials inform deprescribing practices? Dr. Parag Goyal weighs in Read More »

Contact Us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.